ALTEOGEN Inc. (KOSDAQ:196170)

Market Cap	19.24T -6.6%
Revenue (ttm)	215.86B +109.9%
Net Income	141.67B +127.6%
EPS	2,591.24 +122.8%
Shares Out	53.51M
PE Ratio	138.74
Forward PE	55.98
Dividend	371.00 (0.10%)
Ex-Dividend Date	Dec 29, 2025

Volume	444,109
Average Volume	486,402
Open	367,000
Previous Close	366,500
Day's Range	347,500 - 374,500
52-Week Range	317,500 - 569,000
Beta	0.99
RSI	48.98
Earnings Date	May 22, 2026

About ALTEOGEN

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 159
• Stock Exchange: KOSDAQ
• Ticker Symbol: 196170

Financial Performance

In 2025, ALTEOGEN's revenue was 215.86 billion, an increase of 109.87% compared to the previous year's 102.85 billion. Earnings were 141.67 billion, an increase of 127.57%.